AR037394A1 - Antagonistas del receptor de quimiocinas y sus metodos de uso - Google Patents

Antagonistas del receptor de quimiocinas y sus metodos de uso

Info

Publication number
AR037394A1
AR037394A1 ARP020104390A ARP020104390A AR037394A1 AR 037394 A1 AR037394 A1 AR 037394A1 AR P020104390 A ARP020104390 A AR P020104390A AR P020104390 A ARP020104390 A AR P020104390A AR 037394 A1 AR037394 A1 AR 037394A1
Authority
AR
Argentina
Prior art keywords
group
substituted
aromatic
aliphatic group
aliphatic
Prior art date
Application number
ARP020104390A
Other languages
English (en)
Inventor
Jay R Luli
Yoshisuke Nakasato
Etsuo Ohshima
Hiroki Sone
Osamu Kotera
Kenneth G Carson
Shomir Ghosh
Amy M Elder
Karen M Mattia
Geraldine C B Harriman
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en
Application filed by Millennium Pharm Inc, Kyowa Hakko Kogyo Kk filed Critical Millennium Pharm Inc
Publication of AR037394A1 publication Critical patent/AR037394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)

Abstract

Compuestos, composiciones farmacéuticas, profármacos y métodos para tratar o prevenir el reclutamiento y/o activación de los leucocitos aberrantes. Un compuesto que tenga la fórmula (1) o su sal fisiológicamente aceptable, donde: n es 1 a 4; M es >NR2 ó >CR1R2; R1 es -H, -OH, -N3, un halógeno, un grupo alifático, un grupo alifático sustituido, un grupo aminoalquilo, -O-(grupo alifático), -O-(grupo alifático sustituido), -SH, -S-(grupo alifático), -S-(grupo alifático sustituido), -OC(O)-(grupo alifático), -O-C(O)-(grupo alifático sustituido), -C(O)O-(grupo alifático), -C(O)O(grupo alifático sustituido), -COOH, -CN, -CO-NR3R4, -NR3R4 ó R1 es un enlace covalente entre átomo del anillo en posición M y un átomo de carbono adyacente del anillo que contiene M; R2 es -OH, un halógeno, un grupo acilo, un grupo acilo sustituido, -NR5R6, un grupo alifático, un grupo alifático sustituido, un grupo aromático, un grupo aromático sustituido, un grupo benzilo, un grupo benzilo sustituido, un grupo heterocíclico no aromático, un grupo heterocíclico no aromático sustituido, -O-(grupo aromático sustituido o no sustituido), -O-(un grupo alifático sustituido o no sustituido), -C(O)-(grupo aromático sustituido ó no sustituido) ó -C(O)-(un grupo alifático sustituido ó no sustituido); R3, R4, R5 y R6 son independientemente -H, un grupo acilo, un grupo acilo sustituido, un grupo alifático, un grupo alifático sustituido, un grupo aromático, un grupo aromático sustituido, un grupo benzilo, un grupo benzilo sustituido, un grupo heterocíclico no aromático o un grupo heterocíclico no aromático sustituido; ó R1 y R2, R3 y R4, ó R5 y R6 junto con el átomo al que se unen, forman un anillo carbocíclico o heterocíclico no aromático sustituido o no sustituido; R70 y R71 son independientemente -H, -OH, -N3, un halógeno, un grupo alifático, un grupo alifático sustituido, un grupo aminoalquilo, -O-(grupo alifático), -O-(grupo alifático sustituido), -SH, -S-(grupo alifático), -S-(grupo alifático sustituido), -OC(O)-(grupo alifático), -O-C(O)-(grupo alifático sustituido), -C(O)O-(grupo alifático), -C(O)O-(grupo alifático sustituido), -COOH, -CN, -CO-NR3R4, -NR3R4, un grupo acilo, un grupo acilo sustituido, un grupo benzilo, un grupo benzilo sustituido, un grupo heterocíclico no aromático, un grupo heterocíclico no aromático sustituido, -O-(grupo aromático sustituido o no sustituido); R72 y R73 son independientemente -OH, -N3, un halógeno, un grupo alifático, un grupo alifático sustituido, un grupo aminoalquilo, -O-(grupo alifático), -O-(grupo alifático sustituido), -SH, -S-(grupo alifático), -S-(grupo alifático sustituido), -O-C(O)-(grupo alifático), -O-C(O)-(grupo alifático sustituido), -C(O)O-(grupo alifático), -C(O)O-(grupo alifático sustituido), -COOH, -CN, -CO-NR3R4, -NR3R4, un grupo acilo, un grupo acilo sustituido, un grupo benzilo, un grupo benzilo sustituido, un grupo heterocíclico no aromático sustituido, un grupo heterocíclico no aromático sustituido, -O-(grupo aromático sustituido o no sustituido); Z es un resto de fórmula (2); X1 es -CH2-O-, -O-CH2-, -S-, -CH2-, CH2-CH2-, -CH2-S-, -S-CH2-, -NRc-CH2-, -CH2-NRc, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc, un enlace, -O-, ó -CO-NRc-; Rc es -H, un grupo alifático, un grupo alifático sustituido, un grupo aromático, un grupo aromático sustituido, un grupo benzilo ó un grupo benzilo sustituido; los anillos A y B son independientemente no sustituidos o sustituidos; dicho grupo acilo es un carbonilo alifático, carbonilo aromático, alifático sulfonil o aromático sulfonil; dicho grupo alifático es un alquil C1-6, alquenil o alquinil; dicho grupo aromático se selecciona entre el grupo formado por fenil, 1-naftil, 2-naftil, 1-antracil, 2-antracil, N-imidazolil, 2-imidazolil, 4-imidazolil, 5-imidazolil, 2-tienil, 3-tienil, 2-furanil, 3-furanil, 2-pirrolil, 3-pirrolil, 2-piridil, 3-piridil, 4-piridil, 2-pirimidil, 4-pirimidil, 5-pirimidil, 3-piridazinil, 4-piridazinil, 3-pirazolil, 4-pirazolil, 5-pirazolil, 2-pirazinil, 2-tiazolil, 4-tiazolil, 5-tiazolil, 5-tetrazolil, 2-oxazolil, 4-oxazolil, 5-oxazolil, tetrahidranaftil, 2-benzotienil, 3-benzotienil, 2-benzofuranil, 3-benzofuranil, 2-indolil, 3-indolil, 2-quinolinil, 3-quinolinil, 2-benzotiazolil, 2-benzooxazolil, 2-benzimidazolil, 1-isoquinolinil, 3-quinolinil, 1-isoindolil, 3-isoindolil, acridinil, 3-benzisoxazolil, benzociclopentil, benzociclohexil; dicho grupo heterocíclico no aromático es un anillo de 5 a 8 miembros, no aromático, que contiene uno o más heteroátomos independientemente seleccionados entre el grupo formado por nitrógeno, oxígeno o azufre; dicho grupo alifático sustituido se sustituye con uno o más sustituyentes seleccionados entre el grupo formado por el grupo oxo, el grupo epoxi, un anillo heterocíclico no aromático, grupo bencilo, grupo bencilo sustituido, grupo aromático o grupo aromático sustituido reductor, halo, azido, -CN, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, guanidino, oxalo, -C(=NR60)NR21R22, =NR60, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(grupo alifático), -Q-(grupo alifático sustituido), -Q-(aril), -Q.(grupo aromático), -Q-(grupo aromático sustituido), -Q-(CH2)p-(grupo aromático sustituido ó no sustituido), -Q-(grupo heterocíclico no aromático) ó -Q-(CH2)p-(grupo heterocíclico no aromático); dicho anillo heterocíclico no aromático sustituido se sustituye con uno o más sustitutos seleccionados entre el grupo formado por =O, =S, reductor, halo azido, -CN, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, SO3H, guanidino, oxalo, -C(=NR60)NR21R22, =NR60, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(grupo alifático), -Q-(grupo alifático sustituido), -Q-(aril), -Q-(grupo aromático, -Q-(grupo aromático sustituido), -Q-(CH2)p-(grupo aromático sustituido ó no sustituido), -Q-(grupo heterocíclico no aromático) ó -Q-(CH2)p-(grupo heterocíclico no aromático); dicho grupo aromático sustituido, grupo bencilo sustituido, el anillo A cuando es sustituido y el anillo B cuando es sustituido, lo son con uno ó más sustitutos seleccionados entre el grupo formado por electron reductor, halo, azido, -CN, -CONR24R25, -NR24R25, -OS(O)(O)2NR24R25, -S(O)(O)2NR24R25, -SO3H, guanidino, oxalo, C(=NR60)NR21R22, =NR60, -(O)u-(CH2)t-C(O)OR20,-(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(grupo alifático), -Q-(grupo alifático sustituido), -Q-(aril), -Q-(grupo aromático), -Q-(grupo aromático sustituido), -Q-(CH2)p-(grupo aromático sustituido ó no sustituido), -Q-(grupo heterocíclico no aromático) ó -Q-(CH2)p-(grupo heterocíclico aromático);. Q es -O-, -S-; -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -NHC(O)-, -OC(O)NH-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -C(NR23)NHNH-, -NHNHC(NR23)-, -NR24C(O)- ó -NR24S(O)2-; R20, R21 y R22 son independientemente -H, un grupo alifático, un grupo aromático, un grupo heterocíclico no aromático, -NHC(O)-O-(grupo alifático), -NHC(O)-O-(grupo aromático) ó -NHC(O)-O-(grupo heterocíclico no aromático) ó R21 y R22, junto con el átomo de nitrógeno al que están unidos, pueden formar un anillo heterocíclico no aromático sustituido ó no sustituido; R23 es -H, un grupo alifático, un grupo benzilo, un grupo arilo o heterocíclico no aromático; R24 y R25 son independientemente -H, un grupo alifático, un grupo alifático sustituido, un grupo benzilo, un grupo arilo, grupo heterocíclico no aromático ó R24 y R25 junto con el átomo de nitrógeno al que están unidos pueden formar un anillo heterocíclico no aromático sustituido ó no sustituido. R60 es un -H, -OH, -NH2, un grupo aromático ó un grupo aromático sustituido; t es 0 a 3; u es 0 ó 1; p es 1 a 5. Un compuesto que tenga la fórmula (3) o su sal fisiológicamente aceptable, donde: n es un número entero de 1 a 4; M es >NR2, >CR1R2, -O-CR1R2-O- ó -CH2-CR1R2-O-; q1 es un número entero entre 0 a 3; q2 es 0 ó 1; R1 y R2 son los ya definidos más arriba; Z es un resto de fórmula (4), A, C, B y X1 son los ya definidos más arriba y R40 se selecciona entre el grupo de fórmulas (5). Un compuesto que tenga la fórmula (6) ó su sal fisiológicamente aceptable, donde: Z, n y R2 son los ya definidos más arriba.
ARP020104390A 2001-11-21 2002-11-14 Antagonistas del receptor de quimiocinas y sus metodos de uso AR037394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/989,086 US20020169155A1 (en) 1998-09-04 2001-11-21 Chemokine receptor anagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
AR037394A1 true AR037394A1 (es) 2004-11-10

Family

ID=32713949

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020104390A AR037394A1 (es) 2001-11-21 2002-11-14 Antagonistas del receptor de quimiocinas y sus metodos de uso
ARP130101374A AR090829A2 (es) 2001-11-21 2013-04-24 Antagonistas del receptor de quimiocinas y metodos de uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP130101374A AR090829A2 (es) 2001-11-21 2013-04-24 Antagonistas del receptor de quimiocinas y metodos de uso de los mismos

Country Status (24)

Country Link
EP (3) EP2286811B1 (es)
JP (5) JP4889920B2 (es)
KR (3) KR101001092B1 (es)
CN (3) CN1911930A (es)
AR (2) AR037394A1 (es)
AT (1) ATE320431T1 (es)
AU (1) AU2002352772B2 (es)
BR (1) BR0213633A (es)
CA (1) CA2467672C (es)
CY (1) CY1107243T1 (es)
DE (2) DE60209937T4 (es)
DK (1) DK1448566T5 (es)
ES (2) ES2396186T3 (es)
HK (2) HK1063789A1 (es)
IL (3) IL161669A0 (es)
MY (2) MY142646A (es)
NO (1) NO328166B1 (es)
NZ (3) NZ596484A (es)
PL (2) PL403800A1 (es)
PT (1) PT1448566E (es)
SG (2) SG165152A1 (es)
SI (1) SI1448566T1 (es)
TW (1) TWI308568B (es)
ZA (1) ZA200403530B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
KR20100093103A (ko) * 2007-12-03 2010-08-24 노파르티스 아게 고지혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃετρ 억제제로서의 1,2-이치환된 4-벤질아미노-피롤리딘 유도체
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (es) *
JPS5250634B2 (es) 1971-08-23 1977-12-26
JPS61152673A (ja) 1984-12-26 1986-07-11 Kyowa Hakko Kogyo Co Ltd ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
WO1989010369A1 (en) 1988-04-28 1989-11-02 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
AU2028892A (en) 1991-05-23 1992-12-30 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
CA2114009A1 (en) 1991-07-23 1993-02-04 Jesse K. Wong Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
DE69333885T2 (de) 1992-11-10 2006-09-14 Genentech, Inc., South San Francisco C-c ckr-1, ein c-c chemokin rezeptor
WO1996031469A1 (en) * 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
IL124557A0 (en) * 1995-12-15 1998-12-06 Novo Nordisk As Compositions for reducing blood glucose and/or inhibiting the activity of cgrp
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2002524461A (ja) * 1998-09-04 2002-08-06 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
WO2001009137A1 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ATE319775T1 (de) 1999-10-20 2006-03-15 Kingspan Holdings Irl Ltd Zellulärer kunststoff auf basis phenolharz
TW503427B (en) 2000-07-25 2002-09-21 Koninkl Philips Electronics Nv Display tube comprising a mask with vibration damping means
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
DE102011084910A1 (de) 2011-10-20 2013-04-25 Wobben Properties Gmbh Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

Also Published As

Publication number Publication date
CN1585772A (zh) 2005-02-23
KR100919346B1 (ko) 2009-09-25
PL369599A1 (en) 2005-05-02
TW200303197A (en) 2003-09-01
CN1911930A (zh) 2007-02-14
SG165152A1 (en) 2010-10-28
ES2260497T3 (es) 2006-11-01
JP2015083577A (ja) 2015-04-30
NO328166B1 (no) 2009-12-21
JP2005510565A (ja) 2005-04-21
BR0213633A (pt) 2004-08-24
EP2286811B1 (en) 2012-09-05
KR20070118146A (ko) 2007-12-13
EP1688418B1 (en) 2017-03-15
JP2013209393A (ja) 2013-10-10
IL161669A0 (en) 2004-09-27
NO20042500L (no) 2004-06-15
PT1448566E (pt) 2006-08-31
MY146601A (en) 2012-08-30
EP1688418A2 (en) 2006-08-09
IL181191A0 (en) 2007-07-04
DE60209937D1 (de) 2006-05-11
IL161669A (en) 2010-12-30
KR20100010952A (ko) 2010-02-02
CN104031054A (zh) 2014-09-10
CN1585772B (zh) 2014-06-04
DE60209937T2 (de) 2006-11-30
DK1448566T3 (da) 2006-07-31
EP1448566A2 (en) 2004-08-25
EP1448566B3 (en) 2009-04-08
ZA200403530B (en) 2005-07-28
NZ596484A (en) 2013-05-31
JP2010229136A (ja) 2010-10-14
EP2286811A1 (en) 2011-02-23
AU2002352772A1 (en) 2003-06-10
IL181191A (en) 2012-10-31
DE60209937T4 (de) 2009-10-29
CA2467672A1 (en) 2003-06-05
JP4889920B2 (ja) 2012-03-07
NZ532827A (en) 2007-09-28
PL403800A1 (pl) 2013-08-19
PL217918B1 (pl) 2014-09-30
ES2396186T3 (es) 2013-02-19
TWI308568B (en) 2009-04-11
EP1688418A3 (en) 2008-05-14
MY142646A (en) 2010-12-15
DK1448566T5 (da) 2009-08-03
CA2467672C (en) 2011-06-28
AU2002352772B2 (en) 2006-10-26
KR20040064283A (ko) 2004-07-16
JP5936669B2 (ja) 2016-06-22
KR101001092B1 (ko) 2010-12-14
KR100952767B1 (ko) 2010-04-14
SG195393A1 (en) 2013-12-30
SI1448566T1 (sl) 2006-08-31
NZ585746A (en) 2011-12-22
HK1063789A1 (en) 2005-01-14
ATE320431T1 (de) 2006-04-15
HK1154504A1 (en) 2012-04-27
EP1448566B1 (en) 2006-03-15
ES2260497T7 (es) 2009-11-05
CY1107243T1 (el) 2012-11-21
JP2016138122A (ja) 2016-08-04
AR090829A2 (es) 2014-12-10
JP5878494B2 (ja) 2016-03-08

Similar Documents

Publication Publication Date Title
AR037394A1 (es) Antagonistas del receptor de quimiocinas y sus metodos de uso
WO2009057769A1 (ja) 新規スルホン酸塩及びその誘導体、光酸発生剤並びにこれを用いたレジスト材料及びパターン形成方法
AU2006222032B2 (en) Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-Binaphthalene-2, 2'diol
PL296439A1 (en) Method of obtaining novel aromatic amidine derivatives and their salts
JP5140354B2 (ja) 感光性組成物、該感光性組成物に用いる化合物及び該感光性組成物を用いたパターン形成方法
PT1375503E (pt) Derivados dioxino e sua utilização como agonistas da dopamina
FR2932483A1 (fr) Composes utiles pour le traitement des cancers.
NZ574705A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EA200300286A1 (ru) Агонисты активируемых пероксисомальным пролифератором рецепторов
NO991957L (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO161855C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive 4-(3-trifluor-metylfenyl)-1,2,3,6-tetrahydropyridin-derivater.
KR940014332A (ko) 레트로비루스성 프로테아제 효소의 저해제로서 유용하고 항-hiv제로서 작용하는 신규한 화합물 및 이들의 생산 방법
CA3188131A1 (en) Polycyclic amines for opioid receptor modulation
FI88795C (fi) Foerfarande foer framstaellning av tienyletylaminer
KR830000884B1 (ko) 요소 및 아미도 유도체의 제조방법
JP2005510565A5 (es)
Katritzky et al. New 1 H-benzotriazole-mediated synthesis of N, N′-disubstituted thioureas and carbodiimides
NO174200B (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser
NZ203954A (en) N,n'-disubstituted polymethylene diamines
EP1675824A1 (en) Somatostatin receptor 1 and/or 4 selective agonists and antagonists
NO20011197L (no) Nye 6-(4-fenylbutoksy)heksylamin derivater og fremgangsmåte for fremstilling av salmeterol
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
Kutschy et al. Synthesis of 2-substituted 5-arylidenethiazolin-4-ones from α, β-unsaturated acyl isothiocyanates
Becher et al. The photochemical rearrangement of isoquinolinium N-acyl ylides to 1-acylaminoisoquinolines via the excited singlet state
JP2009244803A (ja) ポジ型レジスト組成物およびそれを用いたパターン形成方法

Legal Events

Date Code Title Description
FG Grant, registration